Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Roche (RHHBY - Analyst Report) recently announced that it has entered into a license agreement with Biocare Medical, LLC, through one of its wholly-owned subsidiaries, Ventana Medical Systems, Inc.

Ventana Medical manufactures instruments and reagents that automate tissue processing and slide staining for cancer diagnostics. As per the agreement, Biocare will access certain patents and materials related to p63 diagnostics in the research and IVD field.  

Concurrently, Biocare settled its dispute related to the p63 technology with privately-held AsymmetRx Medical, Inc. Hence, Biocare has gained a worldwide license to distribute p63 (4A4) mouse monoclonal primary antibody in both the research and IVD markets from Roche.

Meanwhile, AsymmetRx will terminate all patent infringement litigation. As per the Harvard Medical School patent filings, AsymmetRx currently holds the license for the use of P63 antibody, which primarily helps in the diagnosis of prostate and other cancers.

We note that the dispute started in Jun 2007 when AsymmetRx initiated litigation challenging Biocare’s intellectual property license for p63.

We remind investors that in Jun 2010, Roche signed a license agreement with AsymmetRx Medical, whereby Roche was granted the exclusive license and distribution rights of AsymmetRx’ patented p63 tool.

We are encouraged by the recent developments at Roche. Most importantly, the US Food and Drug Administration (FDA) has approved Roche’s Kadcyla (ado-trastuzumab emtansine or T-DM1) a few days back for the treatment of patients suffering from HER2-positive metastatic breast cancer (mBC).

Roche has partnered with ImmunoGen, Inc (IMGN - Snapshot Report) for Kadcyla.

Roche carries a Zacks Rank #4 (Sell). Nevertheless, other large cap pharma stocks, such as Bayer (BAYRY - Analyst Report) and Eli Lilly and Company (LLY - Analyst Report) currently look attractive with a Zacks Rank #2 (Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
RAMBUS INC RMBS 12.56 +6.53%
DIXIE GROUP DXYN 15.46 +5.31%
BOFL HOLDING BOFI 85.39 +5.08%
NETFLIX INC NFLX 346.93 +4.68%
E COMMERCE C DANG 12.58 +4.14%